Most approaches to genomic medicine address the roughly 2% of the genome that encode proteins, but Syros Pharmaceuticals Inc. is focused on the remaining 98% of the genome where switches that control gene expression could prove the key to addressing many types of cancer, as well as monogenetic diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?